Testing two arthritis drugs for psoriatic arthritis patients
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This trial compares two drugs, apremilast and adalimumab, to see which is more effective for people with psoriatic arthritis who have not responded well to methotrexate. It focuses on joint pain, swelling, and skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have psoriatic arthritis that hasn't improved enough after 3 months of methotrexate.
- Your arthritis must affect your joints, fingers, toes, or the places where tendons attach to bone.
- You must not have taken any biologic treatments or JAK inhibitors before.
- You must not have active serious infections like tuberculosis or hepatitis B or C.
- You must not have had cancer in the last 5 years, or severe heart, liver, or kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medicine (HS-10374) for people with active psoriatic arthritis who have not responded well to standard treatments. It compares the drug to a placebo to see if it reduces joint pain, swelling, and skin symptoms.
This Phase 3 study compares two biologic medicines—guselkumab and golimumab—to see which works better for people with active psoriatic arthritis. It is designed for people whose psoriatic arthritis did not respond well to a prior “TNF-blocking” medicine (or lost response).
This study looks at how well upadacitinib treats enthesitis (pain where tendons or ligaments attach to bone) in people with psoriatic arthritis. Researchers will use ultrasound to measure improvement. The trial is for adults who have already tried at least one biologic drug, including an anti-TNF, without success.
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
This study compares two “treat-to-target” strategies for psoriatic arthritis. One strategy uses imaging to guide treatment changes, and the other uses standard clinic assessments, to see which approach controls symptoms more effectively.
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.